Varicella vaccine

Should the UK introduce varicella vaccine?

Marion Roderick, Athimalaipet V Ramanan, Adam Finn

Perspective on the paper by Cameron et al (see page 1062)

Chickenpox has traditionally been viewed as an irritating but inevitable infection to be endured during childhood, a rite of passage during the preschool years. This benign view persists despite evidence that certain groups, including neonates, adults, pregnant women and the immunocompromised, have higher risk of severe disease. Few data on the incidence of severe complications and death in children are available; however, such information might change our view of the disease, especially considering that such morbidity and mortality may now be regarded as vaccine preventable.

Population incidence is approximately 13–16 cases per 1000 with substantial year-to-year variation with 2–5-yearly 13–16 cases per 1000 with substantial preventable.

The message that emerges from this and previous studies is that severe and fatal varicella occurs predominantly in children in whom one would not predict problems but who could be protected, in most cases directly, by universal immunisation starting around 1 year of age. However many countries, including the UK, do not recommend vaccine for certain high risk groups or their healthy susceptible contacts.

In contrast, universal childhood varicella immunisation has been introduced elsewhere, most notably in the United States, while in Europe it has only been recommended in Germany to date. Experience in the USA over the last decade has taught us a lot. From 1995 to 2000, cases declined by around 20%, the largest reductions being in children aged 1–4 years. Concomitant reductions in infants and adults confirmed reduced transmission (herd immunity). Hospital admissions declined and mortality rates dropped by 66%, from an average of 0.41 death per 1 million population during 1990–1994 to 0.14 during 1999–2001 (p<0.001). The greatest reduction in mortality (92%) was observed, again, among children 1–4 years of age. More recently, varicella outbreaks have been reported particularly in school populations with high uptakes. Overall, attack rates among vaccinated children were generally 11–17% but exceptionally were as high as 40%. Such “break-through infections” resulted in milder but contagious illness presenting a risk to susceptible individuals. Clearly, a single vaccine dose in the second year of life fails to protect 15–20% of recipients and there is some evidence of waning immunity. Consequently, a second routine dose of vaccine is now recommended.

As vaccinated children are less likely to develop shingles, in the long term the incidence of shingles should fall in an immunised population. However, exposure to wild chickenpox in the community may boost immunity levels, suppressing the reactivation of the virus. Therefore, people who have had wild-type chickenpox might get more shingles once herd immunity starts to wane. Some studies have shown an increase in shingles since vaccination began— although rates of shingles were thought to be decreasing before varicella vaccination commenced and one large recent study did not demonstrate a rise. Either way, zoster is also preventable by immunisation; a vaccine containing higher titres of vaccine virus than the childhood vaccine has been shown to be effective in preventing herpes zoster and post-herpetic neuralgia and has been recommended for universal use in persons 60 years of age or older since 2006 in the USA.

So what about adding a two dose course of varicella vaccine to the UK schedule now? The available formulations are the single antigen vaccine and a combination vaccine against measles, mumps, rubella and varicella (MMRV). Seemingly, the simple, obvious and easy thing to do is to switch from MMR to MMRV. There would be no extra trouble or delivery costs, just the difference between the purchase costs of the two vaccines and doubtless the NHS could negotiate a good price for so many doses. However, this ignores the ongoing damage inflicted on public confidence by the MMR scare and its apparently endless reiterations. Despite abundant evidence that MMR vaccine is safe and effective, public confidence continues to be raised and publicised. In this context, there has to be genuine concern that an MMRV programme could result in suboptimal uptake, further damage to the MMR programme and ineffective varicella herd immunity with an epidemiological shift of disease to older age groups and possible increased morbidity due to the higher risk of complications in adults.

The immediate task is therefore to repair the damage done to an understandably confused public, preceded by
some systematic work to establish how best such communication can be achieved, and followed by some careful assessment of the potential acceptability of the MMRV vaccine. In the meantime, a temporary strategy of immunising all teenagers without a history of chickenpox could be implemented without fear of altering the epidemiology of chickenpox. This could prevent cases of severe disease in adults and pregnant women and raise public awareness of the potential and desirability of primary prevention.  


PERSPECTIVES

Arch Dis Child 2007; 92:1051–1052. doi: 10.1136/adc.2007.130518

Authors’ affiliations
Marion Roderick, Athimalaipet V Ramanan, Bristol Royal Hospital for Children, United Bristol Healthcare Trust, Bristol, UK
Adam Finn, Department of Clinical Science at South Bristol, University of Bristol, Bristol, UK

Correspondence to: Adam Finn, Institute of Child Life and Health, Level 6, UBHT Education Centre, Upper Maudlin St, Bristol BS2 8AE, UK; Adam.Finn@bristol.ac.uk

Competing interests: AF has undertaken advisory work for, chaired and spoken at symposia organised by and accepted support to attend work for, chaired and spoken at symposia organised by and accepted support to attend scientific meetings from all the major vaccine manufacturers. Payments for these activities have been made to his employer, the University of Bristol and used to pay for research and training materials and activities.

REFERENCES

Should the UK introduce varicella vaccine?

Marion Roderick, Athimalaipet V Ramanan and Adam Finn

Arch Dis Child 2007 92: 1051-1052 originally published online November 8, 2007
doi: 10.1136/adc.2007.130518

Updated information and services can be found at:
http://adc.bmj.com/content/92/12/1051.1

These include:

References
This article cites 27 articles, 4 of which you can access for free at:
http://adc.bmj.com/content/92/12/1051.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the
box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Epidemiologic studies (1818)
- Child health (3922)
- Stroke (227)
- Immunology (including allergy) (2018)
- Vaccination / immunisation (334)
- Infant health (811)
- Neonatal health (657)
- Bone and joint infections (34)
- Infection (neurology) (287)
- Meningitis (197)
- Pregnancy (528)
- Reproductive medicine (945)
- Rheumatology (522)
- Editor's choice (148)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/